Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + cyclophosphamide + docetaxel + epirubicin + pertuzumab + pyrotinib + trastuzumab
- Development stage
- Preclinical
- Lead developer
- Johnson Matthey
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
A combination chemotherapy and targeted therapy regimen consisting of carboplatin (platinum-based chemotherapy), cyclophosphamide (alkylating agent), docetaxel (taxane), epirubicin (anthracycline), pertuzumab (anti-HER2 monoclonal antibody), pyrotinib (irreversible pan-ErbB receptor tyrosine kinase inhibitor), and trastuzumab (anti-HER2 monoclonal antibody). This combination targets HER2-positive breast cancer with multiple mechanisms of action, including DNA damage, microtubule disruption, and HER2 signaling pathway inhibition.
02
Targets
TOP2A (DNA topoisomerase II)ERBB4 (Erb-b2 receptor tyrosine kinase 4)MicrotubuleDNAERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on carboplatin + cyclophosphamide + docetaxel + epirubicin + pertuzumab + pyrotinib + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + cyclophosphamide + docetaxel + epirubicin + pertuzumab + pyrotinib + trastuzumab.